Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Use of quetiapine in bipolar disorder: a case series with prospective evaluation INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY Suppes, T., McElroy, S. L., Keck, P. E., Altshuler, L., Frye, M. A., Grunze, H., Leverich, G. S., Nolen, W. A., Chisholm, K., Dennehy, E. B., Post, R. M. 2004; 19 (3): 173-174

Abstract

Quetiapine, a new atypical antipsychotic, was added to ongoing treatment of bipolar I outpatients (n=15) for symptoms of illness (mood lability, irritability, psychosis and/or difficulty sleeping). All evaluations were prospectively obtained, with the majority of patients (n=9) showing much or very much improvement on the Clinical Global Impression for Bipolar Disorder (CGI-BP). Somatic complaints were limited. Mean (SD) duration before changes in medication regimens was 134 (100) days. Studies of the use of quetiapine in maintenance treatment of bipolar disorder are warranted.

View details for DOI 10.1091/01.yic.0000110797.97676.c0

View details for Web of Science ID 000221282700010

View details for PubMedID 15107662